The presumed main mechanism by which aspirin lowers adenomatous polyps and CRC risk is by reducing inflammatory mediators through the inhibition of cyclooxygenase-2 (COX-2) activity [5, 6] and subsequent formation of prostaglandin E2 (PGE2) [7]. The gene discussed is PTGS2; the disease is colorectal carcinoma.